Exhibit 99.1

Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting

NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors

Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer

REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohort of its ongoing Phase 1/2 clinical trial of NT219, at the 2021 ASCO Annual Meeting, being held virtually June 4-8, 2021. The Phase 1/2 study is evaluating NT219 as monotherapy for the treatment of solid tumors, in addition to a subsequent dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer.

As of the cutoff date (April 25^th, 2021), six patients have been enrolled into the study, including three subjects with advanced solid tumors in the first cohort receiving 3 mg/kg of NT219 as a single agent, and three subjects in the second cohort receiving 6mg/kg of NT219 as monotherapy.

Initial results from the first dose level cohort revealed NT219 was well-tolerated with minimal adverse events. In addition, a partial response was observed in a patient with refractory gastroesophageal junction cancer, previously treated with four prior lines of therapies. For this patient, who has been treated for 22 weeks, a complete remission was seen at the largest target lesion and at one non-target lesion, while stable disease was observed at the other non-target lesion.

“We are encouraged by these initial safety and efficacy results from this first-in-human study of NT219,” said Alberto Bessudo, M.D., a medical oncologist and hematologist at California Cancer Associates for Research & Excellence, who presented the data at ASCO. “This study is especially compelling because NT219 uniquely targets the IRS protein to degradation by utilizing a covalent, irreversible inhibition strategy. Based on the preclinical results observed to date, by targeting the IRS1/2 and STAT3 pathways NT219 has the potential to significantly shrink tumors, prevent and reverse tumor resistance when administered as a monotherapy, as well as in combination with existing oncology therapies.”

“Our innovative approach to overcoming tumor immune evasion and drug resistance is focused on interactions within the microenvironment of the tumor, not just targeting the tumor as an isolated feature,” said Bertrand C. Liang, M.D., Ph.D., Chief Medical Officer of Purple Biotech. “It has been demonstrated clinically that IRS and STAT3 proteins are central in defining tumor responsiveness to therapy. Indeed, STAT3 has been seen to play a role in treatment response, and IRS is a novel target with recent promising findings and interest in oncology. While still early in the trial, we are very excited by these initial clinical results and expect to report additional data from higher dose levels of this study in the second half of this year.”

NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, known important oncogenic drivers and major drug resistance pathways in hard-to-treat cancers. The primary objectives of the open-label Phase 1/2 trial are to evaluate safety, assess pharmacokinetics, identify the recommended dose to be studied in the Phase 2 portion, and establish preliminary efficacy of NT219. The Phase 1 portion of the study will encompass a dose escalation evaluation of NT219 monotherapy administered weekly in patients with refractory advanced solid tumors. Upon reaching the third dose level of NT219, a second cohort of patients, with recurrent or metastatic squamous cell carcinoma of the head and neck or colorectal adenocarcinoma, will be administered weekly with NT219, and dose escalated, in combination with cetuximab.

About Purple Biotech

Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219 and CM24. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) or colorectal adenocarcinoma in a phase 1/2 study, and an expansion phase of NT219 at its recommended phase 2 level in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1b study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE®) in patients with pancreatic cancer. The Company is also the owner of Consensi®, an FDA-approved fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the U.S. Consensi® is being sold in the U.S. by Burke Therapeutics, the marketing partner of the Company’s U.S. distributor, Coeptis Pharmaceuticals. The Company has also partnered to commercialize Consensi in China and South Korea. The Company’s corporate headquarters are located in Rehovot, Israel. For more information, please visit https://www.purple-biotech.com.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219 and CM24; the process by which early stage therapeutic candidates such as NT219 and CM24 could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2020 and in our other filings with the U.S. Securities and Exchange Commission (“SEC”), including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, https://www.sec.gov.

Company Contact:

Gil Efron

Deputy CEO & Chief Financial Officer

IR@purple-biotech.com

+972-3-933-3121 ext. #105

Chuck Padala

chuck@lifesciadvisors.com

+1 646-627-8390

Media Contact:

Megan Humphreys

megan@mlhconsulting.co

3 

Exhibit 99.2

NASDAQ/TASE: PPBT June 2021 CORPOR A TE PRESEN T A TION

2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words . You should not place undue reliance on these forward - looking statements, which are not guarantees of future performance . Forward - looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward - looking statements . Important factors that could cause or contribute to such differences include, among others, risks relating to : the plans, strategies and objectives of management for future operations ; product development for NT 219 and CM 24 ; the process by which early stage therapeutic candidates such as NT 219 and CM 24 could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration ; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes ; our ability to successfully develop and commercialize our pharmaceutical products ; the expense, length, progress and results of any clinical trials ; the lack of sufficient funding to finance the clinical trials ; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry ; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products ; the difficulty of predicting actions of the U . S . Food and Drug Administration or any other applicable regulator of pharmaceutical products ; the regulatory environment and changes in the health policies and regimes in the countries in which we operate ; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market ; the introduction of competing products ; patents attained by competitors ; dependence on the effectiveness of our patents and other protections for innovative products ; our ability to obtain, maintain and defend issued patents ; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action ; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our in our Annual Report on Form 20 - F for the year ended December 31 , 2020 and in our other filings with the U . S . Securities and Exchange Commission (the “SEC”), including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports . These are factors that we believe could cause our actual results to differ materially from expected results . Other factors besides those we have listed could also adversely affect us . Any forward - looking statement in this presentation speaks only as of the date which it is made . We disclaim any intention or obligation to publicly update or revise any forward - looking statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law . You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, http : //www . sec . gov .

3 Ou r T ransformatio n int o Oncology Established TASE listing N A S D A Q I PO CONSENSI® NDA submission 2 0 11 2 0 13 2 0 15 2017 Acquisition of CONSENSI® NDA approval & Acquisition of NT219 – Phase 1/2 initiation, TyrNovo/ China FameWave/ CONSENSI® US CM24 – Phase NT219 partnership CM24 launch 1b/2 initiation O nco l og y Pivot 2017 2018 2019 2020 2021

4 Busine s s Highlights S t ro n g b a l a n c e shee t a nd c a s h position Purple Biotech (NASDAQ/TASE: PPBT) CM24 - First - in - class α - CEACAM1 mAb, validating clinical collaboration with Bristol Myers Squibb NT219 - First - in - class, small molecule, dual inhibitor of IRS 1/2 and STAT3 H2:21 - Two phase 1 study readouts $61M cash as of December 31 st , 2020 Cash runway through 2024 ADSs outstanding: 17.5M

5 Advancing Clinical - s t ag e Nove l Oncolog y Therapies Multiple data read - outs expected in the next 12 months Program Indication Preclinical P h as e 1 P h as e 2 P h as e 3 Partner V a l u e Drivers CM24 (CEACAM - 1) Solid tumors (monotherapy) (Completed) Expansion arms on RP2D: Initiation Q4:21 Topline data: H2:21 Solid tumors (combination with nivolumab) NSCLC (combination with nivolumab) Pancreatic Cancer (combination with nivolumab and nab - paclitaxale) NT219 (IRS 1 / 2 & STAT3) Solid tumors (monotherapy) Expansion arms on RP2D: Initiation Q4:21 Topline data: H2:21 R/M SCCHN & CRC (dose escalation with cetuximab); R/M SCCHN (expansion - combination with cetuximab on RP2D) Done / Ongoing Planned study Expansion

6 Experienced Leadership I s a a c I s rae l Chief Executive Officer Former CEO of BeeContact Ltd . (TASE : BCNT) . NextGen Biomed (TASE : NXGN) E r i c K. Row i nsky , MD Chairman of the Board Former CMO at ImClone, Stemline, Board member at Biogen Inc. G i l E f r o n D e pu t y CE O a n d Chi e f Fina n c ial Officer Former Deputy CEO & CFO at Kamada (NASDAQ:KMDA) Ha d a s Reuven i , P h . D Vic e Pre side n t , R &D Formerly at Keryx (NASDAQ:KERX) Be rt r an d L i ang , MD, Ph.D , MBA/A MP, F AA N Chief Medical Officer Formerly at Biogen Idec, Amgen, NCI Michael Sch i ck l e r , P h .D H e a d o f Clini c a l & R e gul a t o r y Affa i r s Formerly at Hoffmann - La Roche, CEO at CureTech

Advancing Firs t - i n - Class On c ology Therapies CM24 - a n α - CEACAM1 mAb

8 CEACAM 1 * Plays a Key Role i n Cancer Bi o logy 01 | ADHE S ION Horst, 2011 “ CEACAM1 creates a pro - angiogenic tumor microenvironment that supports tumor vessel maturation ” “ Neutrophil extracellular trap - associated CEACAM1 as a putative therapeutic target to prevent metastatic progression of colon carcinoma ” Fe r ri , 2 0 2 0 Tsuzuki, 2020 T s a n g, 2 0 2 0 Blumberg, 2015 “C EACAM1 regulates TIM - 3 - mediated tolerance and exhaustion ” “ CEACAM1 regulates Fas - mediated apoptosis in Jurkat T - cells via its interaction with β - catenin ” Shively, 2013 02 | IMMUNE CELLS/ IMMUNE EXCLUSION 03 | IMMUN O - ONCO L OGY “ Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers” “[Blockade] enhances natural killer cell cytotoxicity against tumor cells through blockade of the inhibitory CEACAM1 / CEACAM5 immune checkpoint pathway ” *Carcinoembryonic Antigen Cell Adhesion Molecule

9 CM24 MOA | Immuno - oncology Markel et al, J Immunol 2002, 2006; Immunology, 2008; Cancer Immunol Immunother 2010; Ortenberg et al, Mol Cancer Ther 2012; Zhou, 2009; Li, 2013; Huang, 2015; Acharya N, et al. J Immunotherapy Canc 8:e911 - 22, 2020. T u m or CD8+T & NK Cells C EA C A M 1 C E A CAM 1 C EA C A M 1 C EA C A M 5 Activation enhanced cytotoxic activity & cytokine production Tumor cell or pAPC T cell TCR Si gn a li n g T I M3 MH C TCR C D 4/8 CD45/148 CE A C A M1 CE A C A M1 G a l - 9 P t dSer

10 CM24 MOA | Adhesion CEACAM1 creates a pro - angiogenic tumor microenvironment that supports tumor vessel maturation. CM24 is proposed to attenuate/block tumor growth and metastatic processes. Rayes RF, et al. Neutrophil Extracellular Trap - Associated CEACAM1 as a Putative Therapeutic Target to Prevent Metastatic Progression of Colon Carcinoma. J Immunol. 2020; Gerstel, D. et al. CEACAM1 creates a pro - angiogenic tumor microenvironment that supports tumor vessel maturation. Oncogene 30, 4275 – 4288 (2011) Neutrophil extracellular trap - associated CEACAM1 as a putative therapeutic target to prevent metastatic progression: Primary Tumor Metastasizing CM24 Metastatic Tumor

11 Significant benefits as both single agent and in combination with α - PD - 1 Anti - can c er Ef f ect F ollowin g T rea tm e nt Preclinical Data With CM24 + TIL and CM24 + α - PD1 • Xenograft, lung lesion, Mel 526 (IV) • Tumor burden was monitored 26 days post last CM24 treatment TIL + IgG TIL + CM24 Naïve Combination index (CI) = 0.15 < 1  synergy

12 • Open - label, multi - dose escalation monotherapy study to assess safety and tolerability • Heavily pre - treated patients with a median of 4 prior regimens (range 2 - 8) Overall, treatment was well tolerated • Most of the responding patients were treated with the highest dose levels of 3 mg/kg & 10 mg/kg • PK analysis revealed non - linearity, modeling recommended to continue administration of higher doses to reach saturation CM24 Phase 1 Monotherapy Trial N o D L T s u p t o 10 mg/kg N o dis c o n t i nu a t i o n of stu d y d r u g d u e to a n AE N o drug r e l a te d mortalities 33 .3 % SD (RECIST) # pts 27 patients: Colorectal 11 Melanoma 7 Ovarian 4 Gastric 3 NSCLC 2 *24 patients evaluated 0.01 mg / k g 1 0.03m g / k g 1 0.1 mg / k g 3 0.3 mg / k g 3 1.0 mg / k g 3 3.0 mg / k g 9 10.0 mg / k g 7 Q2wks x 20 6 - week o b serva t ion q 2 wks X 4

13 1 Target - mediated drug disposition. 2 OPDIVO® is a registered trademark of Bristol - Myers Squibb. Ctrough is the drug concentration reached by CM24 before the next dose is administered PK/PD Modeling Provides Dosage & Schedule Guidance Simulated TMDD 1 saturation at Ctrough with Q2W regimen • Consistent with observed PK showing high clearance at doses <10 mg/kg, plot shows low TMDD saturation at low doses • 10 mg/kg has a broad range of saturation, and >10 mg/kg, Q2W dose is needed for saturation across population • Nivolumab administered Q2W or Q4W, representing good clinical and commercial fit for CM24 The Phase 1b/2a study will continue escalating the CM24 dose above 10mg/kg q2wk, in combination with nivolumab

14 Large Market Op p ortunit y i n NS C L C & Pancreatic Cancer • CEACAM1 expression correlates with poor prognosis in NSCLC and Pancreatic cancer 1 • Preclinical data support significant synergy • Receptor saturation with CM24 is better achieved with a Q2W regimen, aligning with the nivolumab regimen • NSCLC accounts for ~200K new cases/year in the US; with a 5 - year relative survival rate of 23% 2 • Immunotherapy is now recommended as first line therapy in all patients with NSCLC and no driver mutations 3 • 5 - year overall survival rates with chemotherapy in 2L is 2.6% and with I/O Opdivo® is 13.4% 4 • Pancreatic Cancer accounts for ~60K new cases/year in the US; with a 5 - year relative survival rate of 10% 2 • I/O approaches have been limited to patients with high microsatellite instability (MSI - H) or high tumor mutational burden (TMB - H) • 5 - year overall survival rates with chemotherapy in 2L is 3% 2 Combining nivolumab with CM 24 in a clinical collaboration with 1 Dango et al, Lung Cancer 2008; 60:426 & Calinescu et al, Journal of Immunology Research 2018: 7169081. 2 American Cancer Society, Cancer Facts & Figures 2019, and the ACS website, https://seer.cancer.gov/statfacts/html/pancreas.html 3 Economopoulou P, Mountzios G. The emerging treatment landscape of advanced non - small cell lung cancer. Ann Transl Med. 2018;6(8):138. doi:10.21037/atm.2017.11.07 4 Gettinger S, et al "Five - year outcomes from the randomized, phase III trials CheckMate 017/057: Nivolumab vs docetaxel in previously treated NSCLC" WCLC 2019; Abstract OA14.04.

15 C M 2 4 Phase 1 / 2 Combination Study Design ( N CT 0 4 7314 6 7 ) A Phase 1/2 open label multi center study of CM24 in combination with: • Nivolumab in selected cancer indications (Phase 1) and NSCLC (Phase 2) • Nivolumab and nab - paclitaxel in pancreatic cancer (Phase 2) Primary endpoints: Phase 1: Evaluate the safety, PK and the MTD/RP2 dose Phase 2: Evaluate preliminary efficacy in 2nd line NSCLC and pancreatic cancer Measurement of CEACAM1 based bio - marker. Exploring further studies in other tumor types as well as monotherapy 2021 2022 202 3 - 24 Doses: 10, 15, 20mg/kg q2wk + nivolumab (480mg q4w) 3+3 design 9 ≤ n ≤ 18 Indications: NSCLC, Pancreatic, Ovarian, CRC, Melanoma, Papillary Thyroid Carcinoma Dose Escalation Ex p an s i o n s CM24 (@RP2 dose) + nivolumab (480mg) q4w I/O refractory NSCLC; 2 nd line n=13+14 (Simon 2 Stage Design) CM24 (@RP2 dose) + nivolumab (480mg) q4w + nab - paclitaxel Locally advanced, unresectable pancreatic cancer; 2 nd line n=13+14 (Simon 2 Stage Design) Clinical collaboration with:

Advancing Firs t - i n - Class On c ology Therapies N T 21 9 – A Small Molecule Dual Inhibi t o r o f IRS 1/2 and S T A T3

17 NT 21 9 - Dual Inhibitor o f IR S 1 / 2 & S T A T 3 NT219 IRS1/2 • Scaffold proteins, mediating mitogenic, metastatic, angiogenic and anti - apoptotic signals from IGF1R, IR, IL4R and other oncogenes, overexpressed in multiple tumor types • Regulates major survival pathways such as the PI3K/AKT, MEK/ERK and WNT/β - catenin • Activated as a feedback response to anti - cancer therapies STAT3 • Well - established transcription factor associated with the tumorigenic phenotype • Provides a crucial axis to support cell proliferation and survival • Active in tumor JAK/STAT3 and TGF - β resistance mechanisms 1 Hadas Reuveni et al.; Cancer Res 2013;73:4383 - 4394. 2013 , 2 Machado - Neto, et al. Clinics (Sao Paulo, Brazil) vol. 73,suppl 1 e566s. 11 Oct. 2018, doi:10.6061/clinics/2018/e566s 3 Naokazu Ibuki1,2, Mazyar Ghaffari1,3, Hadas Reuveni4 et al. DOI: 10.1158/1535 - 7163.MCT - 13 - 0842 Published December 2014; 4 Rampias T, Favicchio R, Stebbing J, Giamas G. 2016 May 19;35(20):2562 - 4. doi: 10.1038/onc.2015.392. Epub 2015 Oct 19. PMID: 26477311 5 Flashner - Abramsonet al.. Oncogene. 2016 May 19;35(20):2675 - 80. doi: 10.1038/onc.2015.229. Epub 2015 Jun 29. PMID: 26119932, 6 Sanchez - Lopez E,. Oncogene. 2016 May 19;35(20):2634 - 44. doi: 10.1038/onc.2015.326. Epub 2015 Sep 14. PMID: 26364 6 1 2; PMC I D: PMC4791 2 1 7 . 7 Zhao C, et al. Trends Pharmacol Sci. 2016 Jan;37(1):47 - 61. doi: 10.1016/j.tips.2015.10.001. Epub 2015 Nov 12. PMID: 26576830, 8 Johnson, Daniel E et al. “Targeting the IL - 6/JAK/STAT3 signaling axis in cancer.” Nature reviews. Clinical oncology vol. 15,4 (2018): 234 - 248. doi:10.1038/nrclinonc.2018.8

18 Nove l MOA: IRS De g ra d atio n B y NT 219 Blockin g IG F 1 R - AKT Pathwa y 1 Binding to IRS 1 1 Reuveni et al. Cancer Res 2013 2 Ser - phosphorylation Degrad a ti on 3 Covalent binding to IRS1/2 leads to the dissociation of IRS1/2 from IGF1R Serine phosphorylation prevents re - binding of IRS1/2 to the receptor SURVIVAL APOPTOSIS IRS1/2 is degraded by the proteasome I GF 1 I GF1 R I R S AKT PI 3 K I G F 1 I GF1 R I R S NT AKT I G F 1 I GF1 R I R S pS pS AKT I G F 1 I GF1 R AKT

19 NT219 E f ficacy as Monotherapy Animal model Head & Neck Cancer (SCC - 9) NSG™, PBMCs - injected 1 Drugs α - PD1 Cetuximab (Erbitux®) NT219 20mg/kg NT219 60mg/kg 1 NSG mice were injected SC with SCC - 9 cells. PBMCs (18*10 6 cells per mouse) administered 4 weeks prior to first treatment. NT219, α - PD1, and cetuximab were administered IV (NT219) and IP (α - PD1 and cetuximab) twice a week for 4 weeks. Graph reflects relevant data adapted from 2020 Multidisciplinary Head and Neck Cancers Symposium Poster presentation

20 By blocking both STAT3 and IRS pathways, NT219 prevents tumor resistance and re - sensitizes tumors to anti - cancer therapies S T A T 3 and IRS ar e Essentia l in Therapeutic Resi s tance STA T3 I R S EG FR MEK Tumor Regres s ion E RK P I 3K AKT Tumor Survival Tumor Survival B uparlisib Ruxolitinib Erlotinib Blocking survival pathways NT219 NT219 S TA T 3 I R S ONCOPROTEIN DR U G MEK / ERK TUMOR R E G R ES S ION Proof of Concept: PDX model of Head and Neck Cancer Control (n=6) Erlotinib (n=8) Erlotinib+NT219 (n=6) E rl ot i n i b +R uxo l i t i n ib ( n =6) Erlotinib+Buparlisib (n=6) Erlotinib+Ruxolitinib+Buparlisib (n=8)

Control NT219 Cetuximab Cetuximab+NT219 Treatments on days 0, 3 and 10, cetuximab - 1mg/mouse, 3 mice/group; PBMCs (1.4M cells/mouse) were injected on day 6 21 ** p<0.01, * p<0.02 based on one - way ANOVA with post hoc Tukey’s HSD test NT 21 9 + T ar g eted Therapies Establishe d Ef f icacy i n PDX Models NSCLC Exon 19 deletion EGFR and T790M, biopsy of bone marrow metastasis, patient previously progressed on afatinib and osimertinib R/M SCCHN metastasis, patient previously progressed on chemoradiation, several chemotherapies, and pembrolizumab 0 Control NT219 Osimertinib Osimertinib+NT219 Osimertinib 5 mg/kg, NT219 65 mg/kg, mean tumor volume at the end point, 3 mice/group; 5 0 0 1,0 0 0 1,5 0 0 2,0 0 0 Tumor Volume (mm 3 ) * ** ** * Tumor Volume (mm 3 )

22 N T 21 9 + α - P D 1 Re - sensitize s to Refr a ctory α - P D 1 Tumors PDX Model Humanized PDX of Esophagus Cancer (refractory to pembrolizumab) Drug P e m b r ol i z umab (Keytruda®) * Double autologous model - Tumors & PBMCs are from the same patient (#RA236) | Keytruda - 6mg/kg IP, NT219 - 60mg/kg IV 0 2 00 4 00 6 00 8 00 1 0 0 0 1 2 0 0 0 5 10 15 20 Tumor volume (mm3) Days following treatment initiation Control (n=3) NT219 (n=3) Keytruda (n=3) Keytruda + NT219 (n=3) Autologous PBMCs (2.1 M/mouse)

23 Fir s t Market Op p ortunity Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) Global Data 2018: Head and Neck Squamous Cell Carcinoma: Opportunity Analysis and Forecasts to 2026 ; Internal best current estimates of patient numbers based on external research, 5 major global territories Rationale for combining Cetuximab + NT219 • EGFR and PD(L) - 1 are the only clinically validated targets in SCCHN • < 15% of R/M SCCHN patients respond to Cetuximab • Cetuximab inhibits EGFR signaling and promotes ADCC in EGFR expressing tumors • STAT3 and IRS - to - AKT activation contributes to resistance to cetuximab in SCCHN Targeting the unmet medical need • 1L Standard of care has shifted from chemotherapy towards immuno - oncology + chemotherapy • < 20% of R/M SCCHN patients respond to α - PD1s • 175k new cases/year are expected by 2024 α - PD - 1 + Chemo 1L 60K pts Cetuximab 2L 37K pts N T 219 NT219 + Cetuximab has the potential to become an attractive 2 nd line therapy

24 NT 21 9 Monothera p y and Combination Phase 1 / 2 Stu d y Design ( NCT 04 4 7 4 4 7 0 ) Study title A phase 1/2 study with open - label, dose escalation phase followed by single - arm expansion to assess the safety, tolerability, PK, PD and efficacy of NT219, alone in adults with recurrent or metastatic solid tumors and in combination with Erbitux® (cetuximab) in head and neck cancer Endpoints Primary endpoints: Safety, pharmacokinetics and to determine the MTD Secondary endpoints: Obtain preliminary efficacy data 1 Colorectal Adenocarcinoma pts will be recruited in the Dose Escalation phase Indication TBD (expansion not part of the study protocol) 2020 2023 Do se Es c a l at i o n NT219 q1w 18 ≤ n ≤ 30 Expansion NT219 q1w @ RP2D n=11+18 (Simon 2 stage design) NT219 q1w + cetuximab q1w 9 ≤ n ≤ 18 NT219 + cetuximab in subjects with R/M head and neck cancer 1 Do se Es c a l at i o n E x p a n s io n NT219 q1w + cetuximab q1w n=11+18 (Simon 2 stage design) 2021 2022 NT219 as a single agent in subjects with R/R solid tumors Dose Escalation Design Study D es i g n

25 Ca n cer Type Prior Lines of Th e r a p y Treatment D u ra t i o n ( W ee k s) Best Response* NT219 3mg/kg P a n c r e a tic Cancer 3 8 PD Target lesion : A b se n t PR GE J u n c tion Cancer 4 22 Non target lesion 1: Absent N o n t a r g e t lesion 2: Stable Breast C a n c er 11 8 PD Interim Analysis – SAFETY and R ESPO N SE 3 mg/kg Dose Level as a Single Agent Response Analysis *Interim data • NT219 has been found to be well - tolerated with minimal adverse events • In a patient with refractory GE junction disease, NT219 administration was associated with a partial response (PR): x Complete remission at the largest target lesion and one non - target central mesenteric lymph node x Stable Disease at the other non - target lesion pre - carinal lymph node

26 Busine s s Highlights S t ro n g b a l a n c e shee t a nd c a s h position Purple Biotech (NASDAQ/TASE: PPBT) CM24 - First - in - class α - CEACAM1 mAb, validating clinical collaboration with Bristol Myers Squibb NT219 - First - in - class, small molecule, dual inhibitor of IRS 1/2 and STAT3 H2:21 - Two phase 1 study readouts $61M cash as of December 31 st , 2020 Cash runway through 2024 ADSs outstanding: 17.5M

We are committed to p r ovid i n g cancer patients with fi r s t - in - class therapies to OVERCO M E tu m o r dru g resistance, ENHANCE treatment respons e an d S L OW tu m o r prog r ession

TH A N K YOU Contact Us: ir@purple - biotech.com

App e ndi x A - C M 24

30 CM24 activity is Demonstrated as Single Agent and in Combination with TILS Inhibi t io n o f Melanoma Growth Followin g CM24 and CM24 + TIL T reatment *P<0.05 TG I 71% *P<0.05 TG I 4 5%

31 PHASE 1 PK D A T A T arge t satura t io n was no t r eached with d o se s u p to 1 0 mg/kg Slower clearance with increasing dose Higher half - life with increasing dose 0.1 mg/kg 0.3 mg/kg 1 mg/kg 3 mg/kg 10 mg/kg Predictions with Q3W regimen • Modeling with increased interval between doses demonstrates lower TMDD at 10mg/kg dose • With Q3W, 20mg/kg dosing is not sufficient for saturation across population

App e ndi x B - N T 219

33 Selected Pu b lic a ti o ns Menashe Bar - Eli Michael Karin Michael Cox Alexander Levitzki

Colon cancer LS - 513 cells overexpressing IRS2 demonstrate enhanced  - catenin activity. Targeted inhibition of IRS2 by NT219 or IRS2 - SH RNA, suppresses the increased  - catenin activity and inhibit LS - 513 cell viability. Combination of 5 - FU and NT219 significantly inhibited the growth of CRC tumors in brain, using intracranial model and extended mice survival. 34 AACR Annual Meeting, April 2021, AACR Virtual Special Conference on Epigenetics and Metabolism, Oct 2020, Ido Wolf, MD, Head of Oncology Division, Tel Aviv Sourasky Medical Center IRS2 Active β - C a t e n in β - actin NT219 - + CRC Cell Viability (72hr) NT219 concentrations (  M) 0 . 0 0 . 5 1 . 0 1 . 5 *** * * ** * ** * ** * D ME M iAKT Alpelisib N T - 21 9 I R S2 NT219 downregulates IRS2 and suppresses the  - catenin activity Silencing IRS2 inhibits  - c a t e nin ac ti vi ty NT219 | Suppresses β - Catenin activity in CRC Cells and Inhibited CRC Brai n Metastasis 5 - FU NT219 + 5 - FU In Vitro In Vivo

35 PDX model Pancreatic Cancer Drug Gemcitabine (Gemzar ® ) NT 21 9 | Pancr e ati c Canc er i n Combinat i on wi t h G e mcitab i ne Highly effective anti cancer activity exhibited by NT219 in combination with Gemcitabine

36 PDX model Pancreatic Cancer Drug Gemcitabine (Gemzar®) RNA Sequencing | Analys i s o f T um o rs F o l lowing T r e atment Reduced expression of IRS1, Ki67, FOXM1 & TGFb is exhibited by pancreatic cancer treated with NT219 alone and in combination with gemcitabine

37 Demographics of Patients treated with NT219 3mg/kg (n=3) Median age (range) 74 (69 - 79) Male/Female, n (%) 2(66.6%)/1(33.3%) Race White n (%) 3 (100%) Prior Lines of Therapy 3 n (%) 1 (33.3%) 4, n (%) 1 (33.3%) 11, n (%) 1 (33.3%) Diagnosis, n Pancreatic Cancer 1 Gastroesophag e al J unction Cancer 1 Breast Cancer 1 ECOG, n (%) 1 3 (100%) Median time from initial Diagnosis, Months (range) 62 (22 - 90) N T 21 9 – DEM O GRAPHICS & SAFE T Y 3 mg/k g D os e Level a s a Sing l e Age n t A d v erse E v ent Description Grade 1 n ( # E v ents) G r ade 2 n (#Events) Grade 3 n ( # E v ents) Abdominal Pain 1(2) 1(1) Alanine A m inotr a n s fe ra s e Increased 1(1) Alkaline Phosphatase Increased 1(1)* Aspartate A m inotr a n s fe ra s e Increased 1(1) Back Pain 1(1) Belching 2(2) Cellulitis Left Foot 1(1) Dyspnea 2(2) Fatigue 1(1) Nausea 1(1) 1(1) Rash Pustular 1(1) Retching 1(2) Toxic Encephalopathy 1(1)** *Transient - G2 after 2 weeks, **Transient - less than 24h P atients D em ogra ph i cs Sum m ary o f A d ve r s e E v ents Presented at the ASCO annual meeting June 2021

App e ndi x C - CON S EN S I®

39 CONSE N SI® | F ro m IND to the U .S . Market Celecoxib , a COX - 2 selective NSAID (the active ingredient in Pfizer’s Celebrex®) + Amlodipine a blood pressure - lowering agent (a calcium channel blocker) (the active ingredient in Pfizer's Norvasc®) CONSENSI ® is the only NSAID whose labeling indicates reduction of blood pressure and consequent risk reduction of heart attack, stroke and death Full U.S. Prescribing Information is available at http://www.consensi.com Fixed dose combination of Launched in the USA - Coeptis Pharmaceuticals Partnered in China - CSBio Partnered in S. Korea - Kuhnil Pharmaceutical Purple Biotech’s clinical, regulatory and medical teams developed CONSENSI® internally from IND, through successful Phase III clinical trials, to FDA approval

40 • Primary efficacy endpoint was successfully achieved (P=0.001) • Demonstrated 2.5x better blood pressure reduction than FDA requirement (50% of amlodipine arm) • Demonstrated consistent reduction in all measures of blood pressure • Observed beneficial renal functions: • Additional Phase III/IV clinical trial to scientifically validate the renal benefits (not required for NDA submission) was completed. Topline results were announced in October, 2017 CON S ENS I ® P h as e III T ria l Results * Error bars – standard error of mean Blood Pressure Reduction of Consensi® vs. Amlodipine and Celecoxib* Consensi® demonstrated even better BP reduction than same amount of amlodipine given without celecoxib Measure Consensi ® Amlodipine Creatinine plasma le v el reduction - 3.22 μmol/L - 2.55 μmol/L P eri p he r al edema (% patients) 8.2% 15.6%

41 Purple Biotech Commercial Drug: CONSENSI® Simultaneous treatment of osteoarthritic pain and hypertension Fixed dose combination of Celecoxib , a COX - 2 selective NSAID (the active ingredient in Pfizer’s Celebrex®) + Amlodipine, a blood pressure - lowering agent (a calcium channel blocker) (the active ingredient in Pfizer's Norvasc®) *Celebrex® is a registered trademark of G.D. Searle LLC (a subsidiary of Pfizer Inc.). Norvasc® is a registered trademark of Pfizer Inc. CONSENSI® is the only NSAID whose labeling indicates reduction of blood pressure and consequent risk reduction of heart attack, stroke and death Full U.S. Prescribing Information is available at: : http://www.consensi.com • Approved for marketing by U.S. FDA on May 31, 2018 • Clinical data showed Consensi™ was more effective at lowering blood pressure than amlodipine alone • Clinical data also demonstrated beneficial renal function measures • Formulated with 200 mg celecoxib and three different dosages (2.5, 5, 10 mg) of amlodipine • Manufactured by Dexcel Pharma – Israel’s largest private pharmaceutical company

42 CON S ENS I ® U.S . T arge t Markets CONSENSI® targets osteoarthritis (OA) patients currently treated with NSAIDs (celecoxib as well as others) who also suffer from existing or newly diagnosed hypertension OSTEOARTHRITIS 50 million patients* N S A I Ds 60 % of all O A Rxs * Arthritis Foundation: http://www.arthritis.org/ ** Hypertension Among Adults in the United States: National Health and Nutrition Examination Survey, 2011 – 2012 ARTHRITIS PREVALENCE* • More than 50 million adults in the U.S. have doc t or - diag n os ed osteoarthritis • 67 million people are expected to have doctor - diagnosed osteoarthritis by 2030 H Y P E R TENSION PREVALENCE** • 29% of U.S. adults older than 18 • 65% of U.S. adults older than 60 COMORBIDITIES • 44% of adults with high blood pressure have osteoarthritis** HYPERTENSION C e l e coxib 24 % of all NSAIDs Consensi ™